RANBAXY

Ranbaxy Laboratories Limited has informed the Exchange regarding a press release dated July 29, 2014 titled "Ranbaxy Q1 FY 2015 (Apr'14-Jun'14) Sales Rs.23.7 Bn Growth registered in Base business profitability".

Ranbaxy Laboratories Limited has informed the Exchange regarding a press release dated July 24, 2014, titled "Ranbaxy and Cipher Announce Signing of Licensing Agreement for Isotretinoin".

Ranbaxy Laboratories Limited has submitted to the Exchange vide letter dated July 24, 2014 a copy of disclosure pursuant to Regulation 13(4), 13(4A) and 13(6) of the SEBI (Prohibition of Insider Trading) Regulations, 1992.

Ranbaxy Laboratories Limited has informed the Exchange that the ESOPs Allotment Committee of Directors at its meeting held on July 14, 2014 has allotted 207,529 Equity Shares on exercise of stock options under the Employees Stock Option Scheme(s) of the Company. The paid-up Equity Share Capital of the Company post allotment is 424,013,339 Equity Shares of Rs.5 each aggregating Rs. 2,120,066,695/-.

Ranbaxy Laboratories Limited has informed the Exchange vide letter dated June 27, 2014 regarding a press release dated June 26, 2014, titled"OHM LABORATORIES TO LAUNCH VALSARTAN TABLETS".

Ranbaxy Laboratories Limited has informed the Exchange that pursuant to Rule 20(3)(vii) of the Companies (Management and Administration) Rules, 2014, the Company has fixed June 20, 2014 as the relevant date to determine shareholders eligible to cast their votes electronically for transacting the items at the said AGM.

Ranbaxy Laboratories Limited has informed the Exchange that the Company has fixed Book Closure from July 19, 2014 to July 28, 2014 for the purpose of Annual general Meeting of the Company to be held on July 28, 2014.

Ranbaxy Laboratories Limited has submitted to the Exchange vide letter dated May 09, 2014 a copy of Disclosure under Regulation 13(4), 13(4A) and 13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992.

Ranbaxy Laboratories Limited has submitted to the Exchange a copy of Press Release dated May 9, 2014 titled "Ranbaxy January- March2014 Sales at Rs.24.4Bn - Achieved sales guidance with Rs.130.4Bn for the 15 months period ended March 2014 -Growth registered in Base business sales and EBITDA"

Ranbaxy Laboratories Limited has informed the Exchange regarding the standalone Results for the period ended on 31-MAR-2014 as follows: Net Sales of Rs. 665703.9 lacs for period ending on 31-MAR-2014. Net Profit / (Loss) of Rs. (87899.5) lacs for the period ending on 31-MAR-2014.

Ranbaxy Laboratories Limited has informed the Exchange regarding the standalone Results for the quarter ended on 31-MAR-2014 as follows: Net Sales of Rs. 122458.6 lacs for the quarter ending on 31-MAR-2014 . Net Profit / (Loss) of Rs. 89785.9 lacs for the quarter ending on 31-MAR-2014.

Ranbaxy Laboratories Limited has informed the Exchange regarding the consolidated Results for the period ended on 31-MAR-2014 as follows: Net Sales of Rs. 1304032.4 lacs for period ending on 31-MAR-2014. Net Profit / (Loss) of Rs. (108525.2) lacs for the period ending on 31-MAR-2014.

Ranbaxy Laboratories Limited has informed the Exchange regarding the consolidated Results for the quarter ended on 31-MAR-2014 as follows: Net Sales of Rs. 243613.2 lacs for the quarter ending on 31-MAR-2014 . Net Profit / (Loss) of Rs. (7365.4) lacs for the quarter ending on 31-MAR-2014.

Ranbaxy Laboratories Limited has submitted to the exchange the standalone & consolidated financial results for the period ended 31-Mar-2014.

The Exchange had sought clarification from Ranbaxy Laboratories Limited with respect to a news item captioned "Sun-Ranbaxy deal hits hurdle". The Company has clarified that "The Company has neither received any Notice nor appeared/represented before the Hon'ble High Court in regard to aforesaid Court case. Further, we have also not been served the Order of the Hon'ble Court. The subject matter is sub-judice and it would not be appropriate for us to comment on this subject".

Ranbaxy Laboratories Limited has submitted to the Exchange vide letter dated April 30, 2014 a copy of Disclosure under Regulation 13(4), 13(4A) and 13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992.

Ranbaxy Laboratories Limited has submitted to the Exchange vide letter dated April 24, 2014 a copy of Disclosure under Regulation 13(4), 13(4A) and 13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992.

Ranbaxy Laboratories Limited has informed the Exchange that the ESOPs Allotment Committee of Directors vide Resolution by Circulation passed on April 14, 2014, allotted 26,747 Equity Shares on exercise of stock options under the Employees Stock Option Scheme(s) of the Company. The paid-up Equity Share Capital of the Company post allotment is 423,805,810 Equity Shares of Rs.5 each aggregating Rs. 2,119,029,050/-.

Ranbaxy Laboratories Limited has informed the Exchange that United States Attorney's Office for the District of New Jersey has issued an administrative subpoena dated March 13, 2014 to Ranbaxy seeking information primarily related to the Company's API Toansa manufacturing facility in India for which a Form 483 was issued by FDA culminating into import alert. The Toansa facility is subject to certain terms of Consent Decree entered against Ranbaxy in January 2012. The Company is fully cooperating with this information request. Ranbaxy is confident that its pharmaceutical products are safe and e

Ranbaxy Laboratories Limited has informed the Exchange regarding the press release dated April 07, 2014 titled, "Sun Pharma to acquire Ranbaxy in a US$ 4 Billion Landmark transaction."

Ranbaxy Laboratories Limited has submitted to the Exchange the Investor Presentation dated April 07, 2014.

Ranbaxy Laboratories Limited has informed the Exchange that Credit Analysis & Research Limited (CARE), has revised credit rating for long term debt instruments issued by the Company, from CARE AA+ (DoubIe A Plus) to CARE AA (Double A). Long term Instruments with CARE AA rating are considered to have high degree of safety regarding timely payment of financial obligations and carry very low credit risk.However, CARE has reaffirmed the CARE A1+(A One Plus) rating assigned to the short term bank facilities of the Company. Short Term Debt Instruments with CARE rating of A1+ are considered to have v

Ranbaxy Laboratories Limited has informed the Exchange that the Company is currently examining processes and controls at all Company's Active Pharmaceutical Ingredients (API) Manufacturing and Quality units. This action has led to temporarily putting on hold shipments from Company's API facilities of the Toansa and Dewas Plants.This voluntary decision was taken as a precautionary measure and out of abundant caution to better allow the Company to assess and review the processes and controls. The Company will resume shipments after reassuring them about the processes and controls at these facili

Ranbaxy Laboratories Limited has submitted to the exchange the standalone & consolidated financial results for the period ended 31-dec-2013.

Ranbaxy Laboratories Limited has informed the Exchange regarding the press release dated February 5, 2014 titled,"Ranbaxy Q4 FY14 Sales Rs.28.6 Bn. YTD Dec 2013 Sales Rs.106.0 Bn - Base business grows by 10%+ QoQ and on YTD basis - Robust growth in EBITDA during the quarter and on YTD"

Ranbaxy Laboratories Limited has submitted to the Exchange a copy of press statement dated January 24, 2014 which is being issued by the Company.

The Exchange had sought clarification from Ranbaxy Laboratories Limited with respect to a news item captioned "Ranbaxy in tie-up to source raw material for Diovan". The Company has clarified that "Company do not disclose individual business transactions as a part of normal course of business, Ranbaxy, as part of its strategy, evaluates alternate viable sourcing of materials from time to time and takes decisions based on the best value that can be derived in the interest of the Company".

Ranbaxy Laboratories Limited has submitted to the Exchange vide letter dated January 16, 2014 a copy of Disclosure under Regulation 13(4), 13(4A) and 13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992.

Ranbaxy Laboratories Limited has informed the Exchange as per the provisions of the Company's Code for Prevention for Insider Trading, trading window will remain closed from January 24, 2014 to February 6, 2014 (both days inclusive) for the employees/directors of the Company.

The Exchange had sought clarification from Ranbaxy Laboratories Limited with respect to a news item captioned "USFDA probes Ranbaxy units - API mftg unit in Toansa". The Company has clarified that "On Saturday, January 11, 2013, Ranbaxy received the form 483 with certain observations as a result of the recent US FDA inspection at its API plant at Toansa, Punjab, India. The Company is assessing the observations, and will respond to the US FDA in accordance with the agency s procedure to resolve the concerns at the earliest. Ranbaxy continues to improve its systems and processes, and remains ful

Ranbaxy Laboratories Limited has informed the Exchange that at the ESOPs Allotment Committee of Directors vide Resolution by Circulation passed on January 10, 2014, allotted 37,281 Equity Shares on exercise of stock options under the Employees Stock Option Scheme(s) of the Company. The paid-up Equity Share Capital of the Company post allotment is 423,779,063 Equity Shares of Rs.5 each aggregating Rs. 2,118,895,315/-.

Ranbaxy Laboratories Limited has informed the Exchange that the ESOPs Allotment Committee of Directors vide Resolution by Circulation passed on January 10, 2014, allotted 37,281 Equity Shares on exercise of stock options under the Employees Stock Option Scheme(s) of the Company. The paid-up Equity Share Capital of the Company post allotment is 423,779,063 Equity Shares of Rs.5 each aggregating Rs, 2,118,895,315/-.

Ranbaxy Laboratories Limited has informed the Exchange regarding a press release dated January 09, 2014, titled "Ranbaxy and EPIRUS Announces Signing of Licensing Agreement for Biosimilar Product; Ranbaxy to market in India and other Emerging Markets, after approval".

Ranbaxy Laboratories Limited has informed the Exchange regarding a Press Release dated January 08, 2014, titled "RANBAXY RECEIVES APPROVAL TO MARKET RAN - DONEPEZIL IN CANADA".

Life Insurance Corporation Limited has submitted to the Exchange vide letter dated December 23, 2013 a copy of disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 along with a copy of Disclosure under Regulation 13(3) and 13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992

Ranbaxy Laboratories Limited has submitted to the Exchange, the clarification on news item titled "Pharma CEO Kin stocking up on Ranbaxy Shares" which appeared in Economic Times dated December 12, 2013. In this regard, the Company has responded as under : 1. Since the identity of the CEO and his relative has not been disclosed in the aforesaid news item, therefore the Company are unable to provide any information/disclosure about the purchase of shares by the said person in the Company. 2. Daiichi Sankyo Company, Limited (Promoters of the Company) have confirmed that they have no intention

Ranbaxy Laboratories Limited has informed the Exchange that the Allotment Committee of Directors through Resolution by Circulation passed on December 11. 2013, allotted 600,000 Equity Shares of Rs. 5 each for cash at par to Ranbaxy ESOP Trust (Trust), set up to administer Ranbaxy Employee Stock Option Plan-2011. The Trust would allocate the shares to the employees of the Company and of its subsidiaries on exercise of stock options from time to time under Ranbaxy Employee Stock Option Plan - 2011.The paid-up Equity Share Capital of the Company post allotment is 423,741,782 Equity Shares of Rs.

Ranbaxy Laboratories Limited has informed the Exchange regarding a press release dated November 20, 2013 titled "RANBAXY COMPLETES 20 YEARS IN UKRAINE".

Ranbaxy Laboratories Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on October 29, 2013 have approved change of financial year of the Company from January-December to April-March effective April 01, 2014. In view of this, the current financial year will be for a period of 15 months i.e. January, 2013 to March, 2014.

Ranbaxy Laboratories Limited has informed the Exchange regarding the consolidated Results for the quarter ended on 30-SEP-2013 as follows: Net Sales of Rs. 275017.4 lacs for the quarter ending on 30-SEP-2013 against Rs. 263320.3 lacs and Rs. 265139.1 lacs for the quarters ending on 30-JUN-2013 and 30-SEP-2012 respectively. Net Profit / (Loss) of Rs. (45416.9) lacs for the quarter ending on 30-SEP-2013 against Rs. (52424.4) lacs and Rs. 75417.3 lacs for the quarters ending on 30-JUN-2013 and 30-SEP-2012 respectively.

Ranbaxy Laboratories Limited has informed the Exchange regarding the standalone Results for the quarter ended on 30-SEP-2013 as follows: Net Sales of Rs. 138184.2 lacs for the quarter ending on 30-SEP-2013 against Rs. 139509.6 lacs and Rs. 142803.8 lacs for the quarters ending on 30-JUN-2013 and 30-SEP-2012 respectively. Net Profit / (Loss) of Rs. (84223.2) lacs for the quarter ending on 30-SEP-2013 against Rs. (60880.9) lacs and Rs. 55219.2 lacs for the quarters ending on 30-JUN-2013 and 30-SEP-2012 respectively.

Ranbaxy Laboratories Limited has submitted to the exchange the standalone & consolidated financial results for the period ended 30-sep-2013.

Ranbaxy Laboratories Limited has informed the Exchange regarding a Press Release dated October 29, 2013 titled "Ranbaxy Q3 CY 2013 Sales Rs.27.5 Bn. YTD Sep 2013 Sales Rs.77.5 Bn".

Ranbaxy Laboratories Limited has informed the Exchange regarding a press release dated October 21, 2013 titled "Ranbaxy receives CDSCO approval to market Synriam(TM) in India for treatment of malaria caused by Plasmodium vivax parasite".

Ranbaxy Laboratories Limited has informed the Exchange that the ESOPs Allotment Committee of Directors vide Resolution by Circulation passed on October 11, 2013, allotted 12,273 Equity Shares on exercise of stock options under the Employees Stock Option Scheme(s) of the Company. The paid-up Equity Share Capital of the Company post allotment is 423,141,782 Equity Shares of Rs.5 each aggregating Rs. 2,115,708,910/-.

Ranbaxy Laboratories Limited has submitted to the Exchange vide letter dated October 11, 2013 disclosure under Regulation 13(6) of the SEBI (Prohibition of Insider Trading) Regulations 1992.

Ranbaxy Laboratories Limited has informed the Exchange that ICRA has assigned the rating of "[ICRA] A1+" (pronounced as A One Plus) to the Company's Commercial Paper (CP)/Short Term Debt (STD) programme for an enhanced amount of Rs.800 crores.

Ranbaxy Laboratories Limited has informed the Exchange that ICRA has assigned the rating of "[ICRA]A1+" (pronounced as A One Plus) to the Company's Commercial Paper (CP)/Short Term Debt (STD) programme for an enhanced amount of Rs. 800 Crores. Earlier CP/STD programme of the Company for Rs.1200 Crores was also assigned the same rating i.e. "[ICRA]A1+" . Instruments with "[ICRA]A1+" rating are considered to have very strong degree of safety regarding timely payment of financial obligations. Such instruments carry lowest credit risk.

Ranbaxy Laboratories Limited has submitted to the Exchange vide letter dated September 27, 2013 a copy of Disclosure under Regulation 13(4), 13(4A) and 13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992.

Ranbaxy Laboratories Limited has informed the Exchange regarding a press release dated September 19, 2013, titled"Ranbaxy Receives Paragraph IV Certication".